Role of US Military Research Programs in the Development of US Food and Drug Administration–Approved Antimalarial Drugs

Lynn W. Kitchen; David W. Vaughn; and Donald R. Skillman

首页> 外文期刊>Clinical Infectious Diseases >Role of US Military Research Programs in the Development of US Food and Drug Administration–Approved Antimalarial Drugs

【24h】

Role of US Military Research Programs in the Development of US Food and Drug Administration–Approved Antimalarial Drugs

机译：美国军事研究计划在美国食品药品监督管理局批准的抗疟药开发中的作用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

US military physicians and researchers helped identify the optimum treatment dose of the naturally occurring compound quinine and collaborated with the pharmaceutical industry in the development and eventual US Food and Drug Administration approval of the synthetic antimalarial drugs chloroquine, primaquine, chloroquine-primaquine, sulfadoxine-pyrimethamine, mefloquine, doxycycline, halofantrine, and atovaquone-proguanil. Because malaria parasites develop drug resistance, the US military must continue to support the creation and testing of new drugs to prevent and treat malaria until an effective malaria vaccine is developed. New antimalarial drugs also benefit civilians residing in and traveling to malarious areas.

机译：美国军事医师和研究人员帮助确定了天然化合物奎宁的最佳治疗剂量，并与制药行业合作开发并最终获得美国食品药品监督管理局的批准，合成抗疟药氯喹，伯氨喹，氯喹-伯氨喹，磺胺多辛-嘧啶胺，甲氟喹，多西环素，氟替林和阿托伐醌-鸟嘌呤。由于疟疾寄生虫会产生耐药性，因此在开发出有效的疟疾疫苗之前，美国军方必须继续支持新药的研发和测试，以预防和治疗疟疾。新的抗疟疾药物也使居住在疟疾地区和前往疟疾地区的平民受益。

著录项

来源
《Clinical Infectious Diseases》 |2006年第1期|67-71|共5页
作者
Lynn W. Kitchen; David W. Vaughn; and Donald R. Skillman;
展开▼
作者单位

Military Infectious Diseases Research Program US Army Medical Research and Materiel Command Fort Detrick Silver Spring Maryland;

Walter Reed Army Institute of Research US Army Medical Research and Materiel Command Silver Spring Maryland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
入库时间 2022-08-18 01:08:58

相似文献

外文文献
中文文献
专利

1. Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations [J] . Lyauk Yassine Kamal, Jonker Dani?l Martijn, Lund Trine Meldgaard Clinical and translational science. . 2019,第5期

机译：在60美元食物和药物管理局批准的药物临床开发中发现与学习与学习建议相比
2. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development [J] . Faucette Stephanie, Wagh Santosh, Trivedi Ashit, Clinical and translational science. . 2018,第2期

机译：2011-2017批准的美国食品和药物管理局核查新分子实体的反向翻译：抗癌药物发展的经验教训
3. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration the class of 2008 [J] . MooreT.J., FurbergC.D. JAMA internal medicine . 2014,第1期

机译：美国食品药品监督管理局批准的2008年级新药的开发时间，临床测试，上市后跟进以及安全风险
4. Chapter 2 U.S. Food and Drug Administration's Program for Chemical Contaminants in Food [C] . M. Bolger, S. Egan, P. South, Intentional and unintentional contaminants in food and feed . 2008

机译：第2章美国食品药品监督管理局食品中化学污染物计划
5. Role of Patient Advocacy Stakeholders in Science-Based Regulatory Policy at the U.S. Food and Drug Administration (FDA) [D] . Kuehn, Carrie Melissa. 2017

机译：患者倡导利益相关者在美国食品和药物管理局（FDA）的科学研究政策中的作用
6. Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations [O] . Yassine Kamal Lyauk, Daniël Martijn Jonker, Trine Meldgaard Lund 2019

机译：美国食品药品监督管理局批准的60种药物在临床开发中的剂量发现与学习建议和确认建议的比较
7. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development [O] . Stephanie Faucette, Santosh Wagh, Ashit Trivedi, 2017

机译：2011-2017批准的美国食品和药物管理局核查新分子实体的反向翻译：抗癌药物发展的经验教训

Role of US Military Research Programs in the Development of US Food and Drug Administration–Approved Antimalarial Drugs

摘要

著录项

相似文献

相关主题

期刊订阅